TY - CHAP M1 - Book, Section TI - Chapter 38A. Perspective on Colonic Neoplasms A1 - Guillem, José G. A1 - Ruby, Jeannine A. A2 - Zinner, Michael J. A2 - Ashley, Stanley W. Y1 - 2013 N1 - T2 - Maingot's Abdominal Operations, 12e AB - The management of colorectal cancer has progressed over the past two decades because of many advances, including those in genetics, pathology, imaging, medical oncology, radiation oncology, and surgery. Within genetics, a number of mutations have been identified that play a causative role in colon carcinogenesis and have led to developments in targeted therapies and genetic testing for familial syndromes. Currently, most patients presenting with an inherited form of colorectal neoplasm can be classified as having adenomatous (familial adenomatous polyposis [FAP], attenuated FAP [AFAP], MUTYH-associated polyposis [MAP], Lynch syndrome, and familial colorectal cancer type X [FCC X])1 or hamartomatous [juvenile polyposis syndrome [JPS] and Peutz-Jeghers syndrome [PJS]) polyps. With the exception of FCC X, genetic testing can now diagnose all of the aforementioned syndromes, thereby making prophylactic risk-reducing surgery a practical option. SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/10/10 UR - accesssurgery.mhmedical.com/content.aspx?aid=57015811 ER -